S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
The Strategic Gold Play You Haven't Heard About (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
NASDAQ:EXEL

Exelixis (EXEL) Stock Forecast, Price & News

$21.88
-0.34 (-1.53%)
(As of 10/3/2023 ET)
Compare
Today's Range
$21.76
$22.24
50-Day Range
$19.60
$22.74
52-Week Range
$14.87
$22.80
Volume
1.43 million shs
Average Volume
2.26 million shs
Market Capitalization
$6.97 billion
P/E Ratio
42.90
Dividend Yield
N/A
Price Target
$25.24

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
15.3% Upside
$25.24 Price Target
Short Interest
Healthy
2.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.75mentions of Exelixis in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$3.06 M Sold Last Quarter
Proj. Earnings Growth
48.61%
From $0.72 to $1.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.93 out of 5 stars

Medical Sector

45th out of 966 stocks

Biotechnology Industry

1st out of 44 stocks


EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL Price History

EXEL Stock News Headlines

Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Exelixis (NASDAQ:EXEL) Research Coverage Started at HC Wainwright
Exelixis (EXEL) Receives a New Rating from H.C. Wainwright
Exelixis (NASDAQ:EXEL) Price Target Raised to $30.00 at Guggenheim
StockNews.com Upgrades Exelixis (NASDAQ:EXEL) to "Strong-Buy"
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Latest Analyst Ratings for Exelixis
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe
Wells Fargo Sticks to Its Buy Rating for Exelixis (EXEL)
Exelixis Inc.
Exelixis Stock Falls On Unusually High Volume (EXEL)
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
8/01/2023
Today
10/04/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
1,223
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$25.24
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+15.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

Net Income
$182.28 million
Pretax Margin
12.21%

Debt

Sales & Book Value

Annual Sales
$1.61 billion
Cash Flow
$0.63 per share
Book Value
$7.68 per share

Miscellaneous

Free Float
309,148,000
Market Cap
$6.97 billion
Optionable
Optionable
Beta
0.66

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Stelios Papadopoulos Ph.D. (Age 75)
    Co-Founder & Independent Chair of the Board
    Comp: $109k
  • Dr. Michael M. Morrissey Ph.D. (Age 62)
    CEO, Pres & Director
    Comp: $2.31M
  • Mr. Christopher J. SennerMr. Christopher J. Senner (Age 55)
    Exec. VP & CFO
    Comp: $1.09M
  • Mr. Jeffrey J. Hessekiel J.D.Mr. Jeffrey J. Hessekiel J.D. (Age 54)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $959.68k
  • Mr. Patrick J. Haley M.B.A.Mr. Patrick J. Haley M.B.A. (Age 47)
    MBA, Exec. VP of Commercial
    Comp: $844.64k
  • Dr. Dana T. Aftab Ph.D. (Age 60)
    Exec. VP of Discovery and Translational Research & Chief Scientific Officer
  • Ms. Susan T. Hubbard
    Exec. VP of Public Affairs & Investor Relations
  • Mr. Gregg Bernier
    VP of Marketing
  • Ms. Laura Dillard
    Exec. VP of HR
  • Dr. Peter Lamb Ph.D. (Age 62)
    Exec. VP of Scientific Strategy













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price forecast for 2023?

16 Wall Street analysts have issued 12 month target prices for Exelixis' shares. Their EXEL share price forecasts range from $18.00 to $32.00. On average, they expect the company's stock price to reach $25.24 in the next year. This suggests a possible upside of 15.3% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2023?

Exelixis' stock was trading at $16.04 at the start of the year. Since then, EXEL shares have increased by 36.4% and is now trading at $21.88.
View the best growth stocks for 2023 here
.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 8,400,000 shares, an increase of 6.6% from the August 31st total of 7,880,000 shares. Based on an average daily volume of 2,230,000 shares, the short-interest ratio is currently 3.8 days. Approximately 2.7% of the company's shares are short sold.
View Exelixis' Short Interest
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our EXEL earnings forecast
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.10. The biotechnology company earned $469.85 million during the quarter, compared to analysts' expectations of $448.59 million. Exelixis had a net margin of 9.58% and a trailing twelve-month return on equity of 6.53%.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.77 billion-$1.88 billion, compared to the consensus revenue estimate of $1.82 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $21.88.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.97 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.51 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 1,223 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -